Canada Responds To Children’s OTC Pain Reliever Shortage Linked To Consumers ‘Panic Buying’

Shortage began in August and has increased the onset of cough/cold season due to consumers’ “stockpiling/panic buying” in response to high levels of activity in COVID-19, RSV, seasonal flu and other viruses, according to Canadian Pharmacists Association. Health Canada has approved imports of Haleon and J&J children’s pain relievers.

• Source: Shutterstock

Relief is expected soon in Canada from a shortage of OTC children’s pain relievers, caused by consumer stockpiling due to concerns about multiple viruses, as Health Canada approves imports of more than 1m products.

The shortage, which began in mid-August and has increased during the fall with the onset of cough/cold and flu season, isn’t linked to supply problems, but to consumers’ “stockpiling/panic buying” in response to high levels of activity in COVID-19, respiratory syncytial

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Supply Chain

OTC Drug, Supplement Trade Groups Argue For Tariff Exemption, International Supply Chain

 

Potential for supply disruption coupled with manufacturers’ costs for moving supply chains to US emphasized by industry trade groups in comments submitted to Department of Commerce on whether pharmaceutical and dietary ingredients should remain exempted from tariffs President Trump has imposed.

Rapidly Changing Market Demands Quick Study From Consumer Health, Personal Care Marketers

 

“It is shifting so quickly. It's shifting underneath our feet,” says NielsenIQ wellness VP Sherry Frey. Even comparing the past year to the preceding eight, “it's just accelerating quicker and quicker, and one of the biggest areas is online.”

China Distribution Disruption Drags Kenvue Results

 

CEO Thibaut Mongon says Kenvue’s results for current quarter will be affected by “lingering impact of the distribution disruption we saw in China,” which “will take a little bit of time to fix.” Also, activist investor Starboard wants to bring “significant changes” to the board at firm’s annual shareholder meeting later in year.

Tariff War Should Steer US Firms To Mapping Out North American Supply Chains

 

Supplies from Mexico and Canada could become even more important to US firms as well as more reliable than their current systems, says Rob Handfield, Bank of America distinguished professor of supply chain management at NC State.

More from HBW Insight

US FDA Supplement Office Chief Eyes ‘Movement’ This Year On NDI Notifications Final Guidance

 

“We've made some progress and really hope to see some movement as we move forward this year,” says FDA Office of Dietary Supplement Programs director Cara Welch.

People On The Move: Appointments At ANEPF, Inula, Opella

 
• By 

A round-up of the latest consumer health people moves: ANEFP elects president; Inula Group appoints CEO; Opella names ANZ head.

Over The Counter: Taking Real-World Evidence Seriously, With IQVIA Consumer Health’s Volker Spitzer

 
• By 

In part 2 of HBW Insight's interview, IQVIA Consumer Health's vice president of global research and development and real-world evidence services, Volker Spitzer, explains how to approach real world evidence so that regulators recognize its validity, in supporting Rx-to-OTC switch applications, for example.